

PRODUCT DATA SHEET



Bioworld Technology CO., Ltd.

CD272 (W153) Peptide

Cat No.: BS9212P

Background

B and T lymphocyte attenuator (BTLA, CD272) is an immunoglobulin domain-containing glycoprotein whose expression is induced during T cell activation. BTLA is similar to CTLA-4 and PD-1, all of which are co-inhibitory receptors belonging to the CD28 family. However, unlike CTLA-4 and PD-1, BTLA does not interact with B7-Ig family counter receptors. Rather, the herpesvirus entry mediator (HVEM), a TNF receptor, acts as a molecular switch that modulates T cell activation by propagating inhibitory signals through BTLA. The BTLA-HVEM interaction is conserved between mouse and human, suggesting that this system is an important pathway regulating lymphocyte activation.

Swiss-Prot

Q7Z6A9

Applications

Blocking

Specificity

This peptide can be used with studies using BS9212 CD272 (W153) pAb.

Purification & Purity

Synthetic peptide CD272 (W153). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.